×
Warby Parker EBITDA 2020-2024 | WRBY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Warby Parker ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Warby Parker EBITDA 2020-2024 | WRBY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Warby Parker ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Abbott Laboratories (ABT)
$199.9B
Stryker (SYK)
$137.7B
Boston Scientific (BSX)
$121.6B
Medtronic (MDT)
$113B
EssilorLuxottica (ESLOY)
$104.4B
Haleon (HLN)
$48.1B
Lonza Group Ag (LZAGY)
$45.4B
ResMed (RMD)
$35B
Koninklijke Philips (PHG)
$29B
Terumo (TRUMY)
$27.9B
Zimmer Biomet Holdings (ZBH)
$21.6B
Baxter (BAX)
$20.1B
Insulet (PODD)
$16.6B
Smith & Nephew SNATS (SNN)
$13.4B
Bio-Rad Laboratories (BIO)
$9.5B
Demant (WILYY)
$9.2B
BellRing Brands (BRBR)
$7.7B
Lantheus Holdings (LNTH)
$7.5B
ICU Medical (ICUI)
$4.3B
TG Therapeutics (TGTX)
$3.9B
Haemonetics (HAE)
$3.9B
Perrigo (PRGO)
$3.8B
GN Store Nord (GNNDY)
$3.8B
Neogen (NEOG)
$3.7B
Prestige Consumer Healthcare (PBH)
$3.6B
Envista Holdings (NVST)
$3.3B
QuidelOrtho (QDEL)
$3.1B
Agios Pharmaceuticals (AGIO)
$2.6B
Maravai LifeSciences Holdings (MRVI)
$2.3B
Green Thumb Industries (GTBIF)
$2.2B